Biogen Deepens Its ALS Footprint With Long-Term Qalsody Safety Registry

Biogen Inc. (BIIB) announced an update on their ongoing clinical study.

Biogen’s New ALS Safety Study Signals Long-Term Bet on Qalsody

The study, officially titled “An Observational Registry-Based Study to Evaluate the Long-Term Safety of Tofersen in People With SOD1-ALS,” tracks how safe Biogen’s ALS drug Qalsody is over many years. It focuses on people with a rare SOD1 gene mutation and aims to show how the drug performs in routine care, which matters for doctors, patients, and payers.

The only treatment in the study is tofersen, marketed as Qalsody, a drug designed to target the SOD1 mutation seen in a subset of ALS cases. Researchers will not change how people receive the drug, but will instead follow real-world outcomes to better understand long-term safety and treatment patterns.

This is an observational study, meaning there is no random assignment to different treatments or a placebo group. Instead, doctors record data from routine clinic visits in Europe and the U.S., and Biogen analyzes this information to see how Qalsody is used and what serious side effects appear over time.

The registry uses a cohort design and follows people going forward from the time they enroll. There is no blinding or masking, and the primary purpose is safety, not to prove that the drug works, but to build a clearer picture of risks, concurrent health issues, and reasons people stop or stay on treatment.

The study is listed as not yet recruiting, with first submission noted as October 31, 2025, which sets expectations for a long setup period. The latest update on February 27, 2026, signals active planning, while the planned minimum duration of seven years means results will unfold slowly but could support the drug’s label and reimbursement over time.

For investors, this update underscores Biogen’s commitment to building a durable ALS franchise around Qalsody, which could support steady revenue if safety remains acceptable. Longer and cleaner safety data may help negotiations with payers and strengthen Biogen’s position against emerging ALS players and gene therapy efforts targeting similar small patient segments.

In a sector where confidence hinges on long-term outcomes, a robust safety registry can help reduce perceived risk around Qalsody and support valuation for Biogen’s neurology pipeline. While near-term earnings impact is limited, ongoing updates and eventual data readouts may act as catalysts for sentiment, especially if competitors struggle to show similar real-world follow-up.

The study is ongoing in its setup and planning phase, and further details are available on the ClinicalTrials portal.

To learn more about BIIB’s potential, visit the Biogen Inc. drug pipeline page.